Getinge Reports Strong Order Intake Despite Challenges
Getinge recently highlighted a notable increase in order intake, reporting a 10.0% growth, with an organic growth rate of 7.4%. This robust performance was echoed by Mattias Perjos, the company's President & CEO, during the latest financial update. Despite facing some temporary delivery challenges, the medtech company remains optimistic about its growth trajectory.
Market Performance Overview
Strong Growth Across Regions
The global demand for Getinge's innovative products continues to thrive. In the recent quarter, the company's order intake demonstrated a remarkable uptick of 10.0%, with organic growth reaching 7.4%. This performance was consistently strong across all regions, particularly highlighting significant growth in consumables related to Cardiopulmonary and ventilator equipment for Critical Care. Particularly notable was the double-digit organic order intake growth in the Bio-Processing sector, especially in key markets.
Sales Challenges in Specific Segments
While there is positive news, there were some declines in specific segments. For instance, organic sales in Acute Care Therapies saw a slight drop, primarily caused by reduced hardware sales in Cardiopulmonary and declining consumable sales in Cardiac Assist. Comparisons to Q3 2023 presented challenges, highlighting the competitive landscape Getinge operates within. Life Science sales also experienced a 2.4% decline, attributed to scheduling shifts of capital goods deliveries, which are now projected for Q4.
Strategic Acquisitions and Future Outlook
Acquisition of Paragonix Technologies
A significant milestone during this quarter was the completion of the acquisition of Paragonix Technologies, Inc. This strategic move positions Getinge well within the growing market for organ transport products. Paragonix's offerings are expected to complement Getinge’s existing portfolio, utilizing shared technologies and an expansive sales force. Additionally, last year’s acquisitions of Healthmark and High Purity New England continue to exceed expectations, promising organic contributions beginning in the upcoming quarter.
Operational Improvements and Certifications
The quarter has also brought noteworthy recognition regarding product compliance, as TÜV SÜD reinstated Getinge's CE certificate for HLS and PLS consumables, which are crucial for ECLS therapy. However, the quarter was not without its issues—temporary production challenges were encountered due to a supplier setback and adjustments related to new packaging solutions. These disruptions led to a shortfall in HLS and PLS sets available for shipment, although deliveries are expected to resume shortly.
Financial Summary
Despite the challenges faced, Getinge's financial performance remained resilient. For the July-September 2024 period, net sales reflected a modest organic increase of 0.2%. The order intake also prospered, achieving a notable rise of 7.4% organically. Adjusted gross profit reached SEK 3,799 million, although the margin saw a decline to 48.3%. Similarly, adjusted EBITA fell to SEK 903 million, with earnings per share slightly down at SEK 2.24. Free cash flow showed a decrease as well, indicating areas for focus moving forward.
Looking Ahead
As Getinge aims for a strong close to 2024, there is a clear commitment from leadership to deliver exceptional value to customers. Perjos expressed a positive outlook for the company’s future endeavors in enhancing healthcare outcomes for patients globally, reiterating the importance of ongoing innovation and operational excellence.
Frequently Asked Questions
What was the order intake growth reported by Getinge?
Getinge reported an impressive order intake growth of 10.0% with an organic growth rate of 7.4% during the latest quarter.
How did Getinge perform in different regions?
All regions showed positive performance, particularly in consumables related to Cardiopulmonary and ventilators in Critical Care, along with strong growth in Bio-Processing.
What challenges did Getinge face in Q3 2024?
Challenges included slight declines in Acute Care Therapies organic sales, attributed to lower hardware sales and temporary disruptions in consumables production.
What recent acquisition did Getinge complete?
Getinge completed the acquisition of Paragonix Technologies, Inc., enhancing its position in the organ transport market.
What is Getinge's outlook for the rest of 2024?
Getinge aims for a strong finish to 2024, focusing on creating value for customers and improving healthcare delivery.
